Learn how NIBR uses next generation sequencing to transform clinical trials and diagnostics in oncology.

NIBR investigator develops technology that uses tumor DNA in the blood for diagnostics

An investigational treatment for an uncommon immunodeficiency disease races into clinical studies.

Researchers from Seattle Children’s and Novartis shed light on developmental brain disorders that lead to intractable epilepsy.

Genome editing advances drug discovery in biomedical research.

Novel PRC2 inhibitor changes the expression of hundreds of genes in lab model

New NIBR President Jay Bradner shares on drug discovery, his leadership style and what’s next for his career in biomedical research.

Ask Alan Frohman how he found out that he had glaucoma, and he'll quickly tell you that there were no warning signs.

When Carl was diagnosed with metastatic prostate cancer, he and his wife Arlene began navigating his cancer journey while still looking to enjoy their retirement – hoping to remain active with family and friends in their retirement community.

Leprosy is one of the world’s oldest infectious diseases – yet there are still around 200,000 cases every year¹. As the only supplier of multidrug therapy, in January 2026 Novartis renewed its partnership to provide the medicine via the WHO, protecting vital access to treatment.